Alcoholism



Testing Doxazosin to Treat Stress Mechanisms in Alcoholism


Condition:   Alcoholism
Interventions:   Drug: Doxazosin;   Other: Placebo
Sponsors:   University of Wisconsin, Madison;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified April 2017


Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment


Condition:   Alcoholism
Interventions:   Drug: Prazosin;   Drug: Placebo
Sponsors:   University of Wisconsin, Madison;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified November 2016


Cognitive Vulnerability Factors in Alcohol-dependence


Condition:   Alcoholism
Interventions:   Behavioral: Diagnostic Interview for Genetic Studies;   Behavioral: Family Informant Schedule and Criteria;   Behavioral: Temperament and Character Inventory;   Behavioral: Barratt Impulsiveness Scale;   Behavioral: Wisconsin Card Sorting Test;   Genetic: blood sample withdrawn
Sponsor:   CHU de Reims
Terminated - verified July 2016


A Novel Compound for Alcoholism Treatment: A Translational Strategy


Condition:   Alcoholism
Interventions:   Drug: PF-05190457;   Behavioral: MI-VF;   Other: Placebo;   Other: Counseling
Sponsor:   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified March 9, 2017


Alcohol Addiction: A Systems-oriented Approach


Condition:   Alcoholism
Intervention:  
Sponsors:   Charite University, Berlin, Germany;   Central Institute of Mental Health, Mannheim
Recruiting - verified September 2016


Validation of a Test System for Development of Medications for Alcoholism


Condition:   Alcoholism
Interventions:   Drug: Naltrexone;   Drug: Placebo
Sponsor:   Technische Universität Dresden
Recruiting - verified August 2016


The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism


Condition:   Alcoholism
Interventions:   Drug: 125 mg AZD0530;   Drug: 50 mg AZD0530;   Drug: Placebo
Sponsor:   Yale University
Recruiting - verified November 2016


Brain Inflammation and Function in Alcoholism


Condition:   Alcoholism
Interventions:   Device: MRI;   Drug: C-11PBR28;   Drug: F-18FDG
Sponsor:   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified March 20, 2017


Pregabalin for Alcohol Dependence


Condition:   Alcoholism
Interventions:   Drug: Pregabalin;   Drug: Placebo
Sponsors:   St. Petersburg Bekhterev Research Psychoneurological Institute;   St.-Petersburg Bekhterev Research Psychoneurological Institute, Russian Federation
Active, not recruiting - verified April 2016


Medication Development in Alcoholism: Investigating PPAR Agonists


Condition:   Alcoholism
Interventions:   Drug: Sugar Pill;   Drug: TRICOR (fenofibrate)
Sponsors:   The Scripps Research Institute;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Completed - verified December 2016


Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence


Condition:   Alcoholism
Interventions:   Drug: Perampanel;   Drug: Placebo
Sponsor:   Yale University
Suspended - verified April 2017


Efficacy and Safety of High Dose Baclofen for Alcohol Dependence


Condition:   Alcoholism
Interventions:   Drug: Baclofen;   Drug: Placebo
Sponsor:   University of North Carolina, Chapel Hill
Recruiting - verified May 2017


Deep Brain Stimulation for Refractory Alcoholism


Condition:   Alcoholism
Intervention:   Procedure: Implantation of Deep Brain Stimulation
Sponsors:   National Institute of Neurological Disorders and Stroke (NINDS);   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Withdrawn - verified November 13, 2015


A Study of LY2940094 in Participants With Alcohol Dependency


Condition:   Alcoholism
Interventions:   Drug: LY2940094;   Drug: Placebo
Sponsor:   BlackThorn Therapeutics, Inc.
Completed - verified February 2017


N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence


Condition:   Alcoholism
Interventions:   Drug: N-acetylcysteine + high-dose naltrexone (150 mg);   Drug: High-dose naltrexone (150 mg) alone;   Drug: Low-dose naltrexone (50 mg) alone
Sponsor:   VA Office of Research and Development
Completed - verified March 2017


Imaging Cannabinoid CB1 Receptors in Alcohol Dependence


Condition:   Alcoholism
Intervention:  
Sponsor:   National Institute of Mental Health (NIMH)
Completed - verified August 28, 2014


Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Participants With Alcohol Dependence (P05718)


Condition:   Alcoholism
Interventions:   Drug: SCH 900435;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified July 2016


GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)


Condition:   Alcoholism
Interventions:   Drug: Alcohol 6%;   Drug: Placebo
Sponsors:   Indiana University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Active, not recruiting - verified December 2016


Medication Development in Alcoholism: Acamprosate Versus Naltrexone


Condition:   Alcoholism
Interventions:   Drug: Acamprosate;   Drug: Naltrexone;   Drug: Placebo
Sponsors:   The Scripps Research Institute;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Completed - verified February 2017


Cannabinoid Receptor Function & Alcoholism


Condition:   Alcoholism
Interventions:   Drug: THC;   Drug: Placebo
Sponsors:   Yale University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Active, not recruiting - verified December 2016


Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism


Condition:   Alcoholism
Intervention:   Drug: Ethanol High Dose, Ethanol Low Dose, and Placebo
Sponsors:   Yale University;   VA Connecticut Healthcare System;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Completed - verified January 2017


GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence


Condition:   Alcoholism
Interventions:   Drug: Thiopental;   Drug: Placebo
Sponsors:   Yale University;   VA Connecticut Healthcare System
Completed - verified November 2016


Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism


Conditions:   Alcoholism;   Schizophrenia
Interventions:   Drug: Glycine;   Drug: placebo
Sponsors:   Yale University;   Stanley Medical Research Institute
Completed - verified February 2017


Alcoholism: Emotion and Thinking


Condition:   Alcoholism
Interventions:   Procedure: Magnetic Resonance Imaging (MRI);   Behavioral: Interviews, cognitive tests, and emotional measurements
Sponsors:   Boston University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA);   VA Office of Research and Development
Recruiting - verified March 2017


Naltrexone Maintenance Treatment of Alcoholism


Condition:   Alcoholism
Interventions:   Drug: Naltrexone Tablet;   Drug: Matched Placebo Tablet
Sponsors:   The Scripps Research Institute;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Completed - verified April 2017

Refine Your Search Advanced Search